NCT05870579
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05870579
Title [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | FRA | ESP | DEU

Facility Status City State Zip Country Details
UCLA Jonsson Comp Cancer Center Los Angeles California 90095 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Shanghai 200032 China Details
Novartis Investigative Site Saint-Cloud Hauts De Seine 92210 France Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Saint-Herblain 44805 France Details
Novartis Investigative Site Cologne North Rhine-Westphalia 50937 Germany Details
Novartis Investigative Site Gliwice 44 101 Poland Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site L'Hospitalet de Llobregat Barcelona 08907 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field